In addition to evaluating these new targeted agents for PBL, other successful strategies that have been used in the setting of MM such as CAR-T and bispecifics against CD38, CD138 or B-cell-maturation antigen (BCMA) are possible options to be considered especially for those with relapsed and refractory PBL. Here, CD38 is linked to Miyoshi myopathy.